NCT00005096View on ClinicalTrials.gov

Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

December 31, 1999

Primary Completion Date

June 30, 2002

Study Completion Date

June 30, 2002

Conditions

Prostate Cancer

Interventions

DRUG

docetaxel

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Rhone-Poulenc Rorer

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Rhone-Poulenc Rorer

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER